How the Rest of the World’s Capacity-Building Impacts the Global Regulatory Dossier
This article was originally published in The Gold Sheet
Emerging nations are supplanting the developed world’s vision of global pharmaceutical regulatory harmonization with one of their own: capacity-building and convergence. A main point of focus will be creating the regulatory review and manufacturing capability needed to launch biosimilars in countries like Brazil and Taiwan.
You may also be interested in...
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.